Pfizer
NEWS
Halozyme Therapeutics announced that it is acquiring Antares Pharma for $960 million in cash. The news caused Antares stock to rocket 47% in premarket trading.
Myovant said that the FDA provided notice it had found deficiencies that will preclude any potential discussion of labeling or post-marketing requirements at this time.
Moderna tapped Jorge Gomez to take over the role of chief financial officer next month upon the retirement of David Meline, the current company CFO.
Some researchers are pointing to the need for an intranasal approach to vaccination in order to block the viral particles from gaining a foothold in the body at the point of entry – the nose.
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
Pfizer has found its replacement for longtime Chief Financial Officer Frank D’Amelio, who announced his retirement from the company five months ago.
The science community is aware of the effectiveness of the mRNA vaccines developed by Moderna and Pfizer-BioNTech. Now, they may be using that technology to treat cancer.
It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.
COVID-19 has killed more than six million people worldwide and almost one million in the U.S. And the pandemic isn’t over yet. Read on for that and more updates about COVID-19.
JOBS
IN THE PRESS